These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22166404)

  • 41. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
    Fan GH; Zhou HY; Yang H; Chen SD
    FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination strategies in tauopathies and synucleinopathies.
    Braczynski AK; Schulz JB; Bach JP
    J Neurochem; 2017 Dec; 143(5):467-488. PubMed ID: 28869766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases.
    Lindestam Arlehamn CS; Garretti F; Sulzer D; Sette A
    Curr Opin Immunol; 2019 Aug; 59():115-120. PubMed ID: 31430650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of repeat and bilateral submandibular gland needle biopsies in Parkinson's disease.
    Adler CH; Serrano GE; Zhang N; Hinni ML; Lott DG; Mehta SH; Sue LI; Intorcia A; Beach TG
    Parkinsonism Relat Disord; 2019 Nov; 68():69-72. PubMed ID: 31621624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. aSynPEP-DB: a database of biogenic peptides for inhibiting α-synuclein aggregation.
    Pintado-Grima C; Bárcenas O; Iglesias V; Santos J; Manglano-Artuñedo Z; Pallarès I; Burdukiewicz M; Ventura S
    Database (Oxford); 2023 Nov; 2023():. PubMed ID: 38011719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology.
    Schaeffer E; Kluge A; Böttner M; Zunke F; Cossais F; Berg D; Arnold P
    Front Cell Dev Biol; 2020; 8():573696. PubMed ID: 33015066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Symmetry of synuclein density in autopsied Parkinson's disease submandibular glands.
    Adler CH; Serrano GE; Shill HA; Driver-Dunckley E; Mehta SH; Zhang N; Glass M; Sue LI; Intorcia A; Beach TG
    Neurosci Lett; 2024 Mar; 825():137702. PubMed ID: 38395191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunologic treatment of Parkinson's disease.
    Jankovic J
    Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
    [No Abstract]   [Full Text] [Related]  

  • 50. Mitochondrial signaling on innate immunity activation in Parkinson disease.
    Magalhães JD; Cardoso SM
    Curr Opin Neurobiol; 2023 Feb; 78():102664. PubMed ID: 36535149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Quest for Anti-α-Synuclein Antibody Specificity-Lessons Learnt From Flow Cytometry Analysis.
    Leupold L; Sigutova V; Gerasimova E; Regensburger M; Zundler S; Zunke F; Xiang W; Winner B; Prots I
    Front Neurol; 2022; 13():869103. PubMed ID: 35911883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies?
    Vidal-Martinez G; Yang B; Vargas-Medrano J; Perez RG
    Front Mol Neurosci; 2018; 11():465. PubMed ID: 30622456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation.
    Torpey JH; Meade RM; Mistry R; Mason JM; Madine J
    Front Neurosci; 2020; 14():561462. PubMed ID: 33177976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunization strategies for Parkinson's disease.
    Ha D; Stone DK; Mosley RL; Gendelman HE
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S218-21. PubMed ID: 22166440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.
    Price DL; Khan A; Angers R; Cardenas A; Prato MK; Bani M; Bonhaus DW; Citron M; Biere AL
    NPJ Parkinsons Dis; 2023 Jul; 9(1):114. PubMed ID: 37460603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?
    Romero-Ramos M; von Euler Chelpin M; Sanchez-Guajardo V
    Hum Vaccin Immunother; 2014; 10(4):852-67. PubMed ID: 24670306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Microfluidic Cell Co-culture Platform for the Study of the Molecular Mechanisms of Parkinson's Disease and Other Synucleinopathies.
    Fernandes JT; Chutna O; Chu V; Conde JP; Outeiro TF
    Front Neurosci; 2016; 10():511. PubMed ID: 27895548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunization as treatment for Parkinson's disease.
    Agbo DB; Neff F; Seitz F; Binder C; Oertel WH; Bacher M; Dodel R
    J Neural Transm Suppl; 2009; (73):311-5. PubMed ID: 20411789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First therapy targeting Parkinson's proteins enters clinical trials.
    Dolgin E
    Nat Med; 2012 Jul; 18(7):992-3. PubMed ID: 22772533
    [No Abstract]   [Full Text] [Related]  

  • 60. Immune receptor for pathogenic α-synuclein.
    Jucker M; Heikenwalder M
    Science; 2016 Sep; 353(6307):1498-1499. PubMed ID: 27708090
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.